W 0 R L D H E A L T.H ORGANIZATION
REGIONAL OFFICE FOR. THE WESTERN PACIFIC BUREAU R.~GIONAL DU PACIFIQUE OCCIDENTAL
•
ORGANISATION MONDIALE DE LA SANTE
REGIONAL COMMITTEE Thirty-eighth session Beijing 8-14 September 1987 Provisional agenda item 12
WPR/RC38/7 Add.1 29 June 1987 ORIGINAL: ENGLISH
SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION: MEMBERSHIP OF THE POLICY AND COORDINATION ADVISORY 00~~1ITTEE Report by the Regional Director Addendum
This is a background document specially prepared for the Regional Committee by the WHO Special Programme of Research, Development and Research Training in Human Reproduction (HRP). It documents the Special Programme's objectives, internal organization, advisory bodies, finances and the activities supported by the Programme in the \vestern Pacific Region. The main purpose of this document is to provide useful background information, which the Committee may wish to refer to and comment on when electing a member to serve on the Policy and Coordination Advisory Committee of the Special Programme.
tVPR/RC38/7 Add. 1
SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION
C 0 N T E N T S
OBJECTIVES INTERNAL ORGANIZATION ADVISORY BODIES FINANCES FOCUS ON THE WESTERN PACIFIC REGION
WPR/RC38/7 Add. 1 SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION
OBJECTIVES The WHO Special Programme of Research, Development and Research Training in Human Reproduction was established in 1972 as the main instrument within WHO and the UN system: to promote, coordinate and support internationally based research in human reproduction and family planning of special relevance to developing countries by: improving the performance of current methods of fertility regulation, development of new and improved methods for fertility regulation, and improving the prevention and management of infertility; and to promote and support national self-reliance in research on fertility regulation in developing countries through institutional development and research training. INTERNAL ORGANIZATION The Programme is organized in four distinct but closely integrated "areas": Research and Development, Resources for Research, Statistics and Data Processing, and Programme Management (see Fig. 1). The Research and Development Area is organized into eight Task Forces covering three main topics: improving the performance of current methods (two Task Forces: Safety and Efficacy of Fertility Regulating Methods, and Behavioural and Social Determinants of Fertility Regulation), development of new and improved methods of fertility regulation (five Task Forces: Long-Acting Systemic Agents for Fertility Regulation, Post-Ovulatory Methods for Fertility Regulation, Vaccines for Fertility Regulation, Methods for the Regulation of Male Fertility and Natural Methods for Fertility Regulation), and Prevention and Management of Infertility (one Task Force). Task Forces may be phased out and new Task Forces may be established. The Resources For Research Area (grants for institution strengthening, training grants and maintenance of a network of collaborating institutions), is organized into regional programmes (Africa, China, Asia except China, and Latin America). It also includes the Programme for Standards and Quality Control of Laboratory Procedures. The Statistics and Analysis Area provides statistical and data processing support for research projects undertaken by the Task Forces. Activities include the statistical design of projects, project organization, project data collection and processing, data monitoring and management, data analysis, and dissemination of research results. It also provides support to the Resources for Research Area in strengthening biostatistical, epidemiological and data processing capabilities in developing countries. The long-term goal is that, while global multicentre projects will continue to be managed statistically from Geneva, individual centres in developing countries should in time assume full statistical responsibility for their own single-centre studies, as well as coordinating their national multicentre projects. Some centres will be strengthened to play a sub-regional role.
WPR/RC38/7 Add.l page 2
Figure 1
WHO SPECIAL PROGRAMME OF RESEARCH~ DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPROD~CTION
DIRECTOR
STATISTICS AND DATA PROCESSING!
~ PROGRAMME MANAGEMENT
I
l RESEARCH
AND DEVELOPMENT I
I
l RESOURCES
FOR RESEARCH
J
-- Task Forces on: Safety and efficacy Behavioural and social determinants Long-acting systemic agents Post-ovulatory methods Vacctnes Male methods Natural methods Infert 111 tY
--- Programmes for: Africa Asla except China China Latln America PROGRA~1~1E FOR STANDARDS AND QUALITY CONTROL OF LABORATORY PROCEDURES
~
WPR/RC38/7 Add.l page 3
The Programme Management Area provided managerial and administrative support to the Programme. The Statistics and Data Processing Area and the Programme Management Area report directly to the Director of the Programme. The Research and Development Area and the Resources for Research Area report through the respective Responsible Officers. ADVISORY BODIES To develop and maintain the highest possible standard for its activities, the Special Programme has established a system of Advisory Bodies for the range of ita activities (see Fig. 2). Advisory bodies related to individual Programme components report to the Director of the Programme, and include: Research and Development: Resources for Research: Steering Committee for the eight Task Forces· Review Group and Toxicology Group Committee on Resources for Research Steering Committee of the Programme for Standards and Quality Control of Laboratory Procedures
The Scientific and Technical Advisory Group advises on the whole Programme and reports to the Director-General of WHO and to the Policy and Coordination Advisory Committee. The Policy and Coordination Advisory Committee acts as an advisory body to the Director-General of WHO. The Policy and Coordination Advisory Committee (PCAC) has its own procedures for the election of members, who are representatives of governments and agencies. For all other Committees of the Programme, members are selected on the basis of scientific and technical competence, serve in their own personal capacity and are appointed for fixed terms, eligible for renewal only once. Effort is made to include female scientists, to ensure an adequate participation of developing country scientists, and to achieve a fair geographical representation. For 1987, Committee membership is as follows: Total number of scientists Total number of female scientists Total number of developing country scientists Number of developed countries Number of developing countries Scientists from AFRO Scientists from AMRO Scientists from EMRO Scientists from EURO Scientists from SEARO Scientists from WPRO
152 40
85 18 33 13
(26%) (56%) (65%)
35
7 50 20 27
WHO SPECIAL PROGRAMME OF RESEARCH., DEVElOPMENT AND RESEAR'CH TRAININ. G IN: HUMAN REPRODllCTION ADVISORY BODIES - - - - - - - - - Director-General POLICY AND COORDINATION ADVISORY COMMITTEE L---~
SCIENTIFIC AND TECHNICAL ADVISORY GROUP Dtrector of the Programme COMMITTEE ON RESOURCES FOR RESEARCH
'
REVIEW GROUP TOXICOLOGY GROUP
I STEERING COMMITTEES OF IASK FORCES LONG-ACTING POSTOVULATORY SYSTEMIC VACCINES METHODS A~ENTS STEERING COMMITTEE OF PROGRAMME FOR STANDARDS /\ND QUALITY CONTROL OF LABORATORY PROCEDURES
I SAFETY AND EFFICACY BEHAVIOURAL AND SOCIAL DETER~1 INANTS MALE METHODS NATURAL METHODS INFERTILITY
WPR/RC38/7 Add.l page 5
Steering Committees Steering Committees exist for all the eight Task Forces in Research and Development, and for the Programme of Standards and Quality Control of Laboratory Procedures. Steering Committees, which meet at least once a year, develop, implement and monitor the strategic plan. Each Committee is composed of 6 to 12 scientists who are appointed for a term of up to three years. Membership can be extended to a maximum of six continuous years. To encourage collaboration, scientists with the required expertise from other programmes active in the field are invited to a special category of membership: the category of Collaborating Programme Scientist. Review Group The Review Group provides technical assessment of research project proposals approved by Steering Committees, including ethical review for projects involving human subjects. The Review Group may recommend approval, approval after amendment, approval with clarification, deferment of disapproval. The Review Group, which meets twice a year is composed of 12-15 independent scientists who are not members of other Committees or principal investigators in studies supported by the Programme. Members are appointed f or a term of three years, renewable only once . Toxicology Group The Toxicology Group reviews projects involving the use of new drugs and devices, recommends appropriate toxicological studies to be carried out before clinical trials, monitors the various stages of clinical research in the context of toxicological requirements. The Group may recommend changes in the research protocol, may disapprove initiation of clinical studies, or may recommend discontinuation of human research for a given drug. The Toxicology Group, which meets twice a year, is composed of 6-12 independent scientists who are not members of other Committees or principal investigators in studi es supported by the Programme. Members are appointed for a term of three years, r enewable only once. Committee on Resources for Research The Committee on Resources for Research plans, monitors and evaluates strategies for the strengthening of capabilities for research i n human r e production in developing countries. These i nclude institutional grants, trai ning grants, s upport to the network of centres, and the Programme for Standards and Qua l i ty Control of Laboratory Pr ocedures. The Committee which meets at least once a year, is composed of 12-13 independent scientists a ppointed for a term of three years, renewable only once, together with representatives from WHO Regional Offices and Collaborating Programmes.
WPR/RC38/7 Add.l page 6
Scientific and Technical Advisory Group (STAG) The STAG reviews the content, scope and dimensions of the Programme, recommends priorities within the Programme, and provides the Director-General and PCAC with a continuous and independent evaluation of the scientific and technical aspects of all the activities of the Programme. The STAG, which meets at least once a year, is comprised of 15-18 members who serve in their personal capacities to represent the broad range of biomedical and other disciplines required for the Programme's activities. They cannot be members of other Committees, principal investigators in studies undertaken by the Programme, or recipient of Special Programme funds. Members are appointed to serve for a period of three years, and will be eligible for immediate reappointment only once. Scientific and Technical Review Committees (STRCs) are ad hoc committees established by STAG to review in-depth individual components of the Programme. Each component is normally subject to such a review every four years. The STRC is composed of two or three selected members of STAG and up to three external consultants. Policy and Coordination Advisory Committee (PCAC) The PCAC acts as an advisory body to the Director-General of WHO making recommendations on matters related to the policies, strategies, financing, overall organization, management and impact of the Programme. The PCAC, which meets once a year, is composed of four categories of membership: the 12 largest financial contributors, 12 countries elected by WHO Regional Committees; up to 3 interested countries and non-governmental agencies elected by PCAC; and 3 permanent members (United Nations Fund for Population Activities, World Bank, and International Planned Parenthood Federation). FINANCES The Programme is supported by voluntary contribution. Twenty-four financial contributors, including six developing countries, have provided funds to the Programme since 1971. In addition, institutions working with the Programme make counterpart contributions in the form of manpower and institutional infrastructure. Although such contributions cannot be quantified with precision, they are most certainly substantial. In some cases, they have been roughly estimated to be at least equal to the input made by the Programme. As can be seen from Fig. 3, income to the Programme increased steadily until 1980. with a maximum of US$19 million. From 1981, there was a steady decrease until 1984 when the income amounted to US$12.5 million. From 1985, income has increased again, reaching an estimated level of some US$21 million for 1987 (as calculated at the beginning of April 1987).
WPR/RC38/7 Add.!
page 7
INCOME AND OOLIGATIQrJS FOR THE PERIOO 1970-1986 AND PROJECTIOf';S FOR 1987
I
I
I
I
7
I
I
I
I
I
I
I
- - - - lncomt - - - - - · Oblr~11on1
·c 3, . I
j
I 1
2-1
,L :___J_ _ _:_ --- "- ____ :._ __ ] . 72 73 74 75 76 71
- .l _ _j 78 79 BO
__ _ j _ __ ;_ _ _j ___ 81 82 83
~~~ 0
_j_LJ_j 84 BS BG 87 l~u . J
WPR/RC38/7 Add.l page 8
The list of financial contributors (in alphabetical order) to the Programme in 1987 is as follows (funds received and pledged as of 8 April
1987): Australia China, People's Republic of Cuba Denmark Finland Germany, Federal Republic of IDRC (Canada) India Mexico Netherlands Nigeria Norway Sweden Thailand UK
ussR 1 United Nations Fund for Population Activities World Bank World Health Organization
The Programme also acts as Executing Agency for UNFPA country projects. The allocation of resources between Research and Development and Resources for Research is generally kept at the ratio of 2:1. Some 70% of the funds for Programme Operations are awarded to scientists/institutions in developing countries. A FOCUS ON THE WESTERN PACIFIC REGION Programme expenditure in the Western Pacific Region, 1972-1987
-------------------------,-------------1 _________________________ 1 : ______________ 1 I I I I I I I
us $
~
Task Forces Collaborating Centres Other Centres Research Training Small Supplies
: I
7,120,938 4,552,371 9;106,051 6,298,684 171,013 27,249,057
: I
: I
: I
: I
: I
: I
: I
: I I
: I I
1 I _________________________ 1 I ______________ 1 I I I
:
TOTAL
~
:
1 1 ______________ I 1 I _________________________ I
lcontribution in kind
WHO SPEC.I.'\L PROGPAI'IME !ill HJ'1AN REPRODUCTION
GEOGRAPHICAl BREAKDOWN OF OBliGATIONS CU~UlATIVE
DUOGETS
FRC~
1972 TO C.URRENT YEAR
CAll FIGURES EXPRESSED IN US ll RFCIO~
f
CGUNT~Y
COll.CENTRES
OTHER CENTRES
TASK FORCES
SHAll SUI>Pll[ S
RF SEAFICif TRAINING
TOTH
WESTERN PACIFIC AUSTRAL lA CHINA DEMOCRAfiC REP. OF VIET-NAM F TJ l
2 78.043 6,591,378 240,819
1.702,519 515,141'. 9,040 4,750 1,3()4,099 155,606 267,854 100,08) 214,475 525 125,000
74,407 4,954,157 2 54.42 8
2 ,054,969 14,381,170 504 r267 4,750
HCNG KONG J AP.\N
59,161 t6o, 74 e 49,490
1,363,260 316,879 417,427 214,475
MALAYS I A NEW ZE.Al AND PHILIPPINES REPUBLIC Of KOREA SINGAPORE TOTAL: 477,705
6,000
664,207 2,0't6,616
1,000
407,854
1,556,766 ) ,595,590 2 ,839 ,4 <;4
4 3. 2 38 1, 2 50
l6'h 132 169, 307
z t264, 540 4,552.371 9.106,051
404,397 7,120.9)8
111,013
6,298,684
27.249,057
==========================:~===============:=========::==========================c=:====~==:~:::::::
GRANO TOTAL:
32,287.285
15,741,274
59,656,462
8'Bo151
l5,05<J,J15
WPR/RC38/7 Add.l page 10
Institutions collaborating with the Special Programme of Research, Development and Research Training in Human Reproduction, by country Australia Flinders University of South Australia, Adelaide Australia National University, Canberra University of Newcastle, Newcastle, N.S.W. University of Sydney, Sydney, N.S.W. Westmead Centre, Department of Medicine, Westmead, N.S.W. University of Queensland, Brisbane, Queensland Deakin University, Victoria ICI Australia, Limited, Ascot Vale, Victoria Monash University, Clayton, Victoria Gordon Institute of Technology, School of Applied Sciences, Geelong, Victoria Monash University, Prince Henry's Hospital, Melbourne, Victoria Commonwealth Serum Laboratories, Parkville, Victoria Royal Melbourne Hospital, Parkville, Victoria University of Melbourne, Parkville, Victoria Department of Agriculture, Animal Research Institute, Werribee, Victoria Chinese University of Hong Kong University of Hong Kong Institute of Philippine Culture, Ateneo de Manila University, Manila Jose Fabella Memorial Hospital, Manila National Family Planning Office, Ministry of Health, Manila Reproductive Biology Centre, Philippine General Hospital, Manila University of Santo Tomas, Sampaloc, Manila University of the Philippines, Ermita, Manila Population Center Foundation, Makati, Metro Manila Notre Dame University, Cotabato City Philippine Heart Centre for Asia, Quezon City University of the Philippines, Quezon City Leyte State College, Tacloban City Korean Research Institute of Chemistry Technology, Chung Nam Yeungnam University College of Arts and Sciences, Kyongsan, Kyongbuk Soon Chun Hyang College of Medicine, Onyang Catholic Medical College, Seoul Chung Ang University, Seoul IPPF - Planned Parenthood Federation of Korea, Seoul Korean Institute for Family Planning, Seoul Seoul National University College of Medicine, Seoul Yonsei University, Seoul University of Singapore, Singapore University of Singapore, Kandang Kerbau Hospital, Singapore
Hong Kong Philippines
Rep. of Korea
Singapore
WPR/RC38/7 Add.l page 11
Hyogo Medical College, Hyogo-ken St. Marianna University School of Medicine, Kawasaki City Kyoto University, Kyoto Niigata University, Niigata Keio University School of Medicine, Tokyo National Medical Center Hospital, Tokyo University of Tokyo Yamagata University School of Medicine, Yamagata New Zealand University of Auckland, Auckland Canterbury Hospital Board, Princess Margaret Hospital, Christchurch University of Otago, Dunedin Beijing Medical College, Beijing Chinese Academy of Medical Sciences, Beijing Ministry of Public Health, Beijing National Research Institute of Family Planning, Beijing Jinan University, Canton Family Planning Research Institute of Sichuan, Chengdu Family Planning Research Institute of Zheijiang, Hangzhou Nanjing Institute of Materia Medica, Nanjing China Welfare Institute, Shanghai Shanghai Institute of Materia Medica Shanghai University of the South Pacific, Suva Malaysia Institute for Medical Research, Kuala Lumpur National Family Planning Board, Kuala Lumpur University of Malaya, Kuala Lumpur Institute of Gynecology and Obstetrics, Hanoi
People's Republic of China
Vietnam
Institutions collaborating in Task Force projects, by country Oral Contraceptives Australia Deakin University, Victoria Gordon Institute of Technology, School of Applied Sciences Geelong, Victoria University of Hong Kong University of the Philippines, Ermita, Manila Reproductive Biology Centre, Philippine General Hospital, Manila Philippine Heart Centre for Asia, Quezon City Seoul National University College of Medicine, Seoul University of Singapore, Kandang Kerbau Hospital, Singapore
Hong Kong Philippines
Rep. of Korea Singapore
WPR/RC38/7 Add.l page 12
Intra-uterine Devices for Fertility Regulation Australia Japan New Zealand Philippines Rep. of Korea Singapore Gordon Institute of Technology, School of Applied Sciences Geelong, Victoria National Medical Center Hospital, Tokyo University of Tokyo University of Otago, Dunedin Jose Fabella Memorial Hospital, Manila Reproductive Biology Centre, Philippine General Hospital, Manila Seoul National University College of Medicine, Seoul University of Singapore, Kandang Kerbau Hospital, Singapore
Long-Acting Systemic Agents For Fertility Regulation Australia Gordon Institute of Technology, School of Applied Sciences Geelong, Victoria University of Sydney, Sydney, N.S.W. University of Otago, Dunedin Canterbury Hospital Board, Princess Margaret Hospital, Christchurch Chinese Academy of Medical Sciences, Beijing Family Planning Research Institute of Zhejiang, Hangzhou China Welfare Institute, Shanghai University of the Philippines, Ermita, Manila Reproductive Biology Centre, Philippine General Hospital, Manila Seoul National University College of Medicine, Seoul University of Singapore, Singapore University of Singapore, Kandang Kerbau Hospital, Singapore
New Zealand
People's Republic of of China Philippines Rep. of Korea Singapore
Methods for the Natural Regulation of Fertility Australia Department of Agriculture, Animal Research Institute, Werribee, Victoria Royal Melbourne Hospital, Parkville, Victoria Monash University, Prince Henry's Hospital, Melbourne, Victoria Westmead Centre, Department of Medicine, Westmead, N.S.W. Kyoto University, Kyoto
WPR/RC38/7 Add.l page 13
New Zealand Philippines Rep. of Korea Singapore
University of Auckland, Auckland University of Santo Tomas, Sampaloc, Manila Seoul National University College of Medicine, Seoul Catholic Medical College, Seoul University of Singapore, Kandang Kerbau, Hospital, Singapore
Female Sterilization Australia New Zealand Philippines University of Sydney, Sydney, N.S.W. University of Otago, Dunedin University of the Philippines, Ermita, Manila Reproductive Biology Centre, Philippine General Hospital, Manila Jose Fabella Memorial Hospital, Manila Seoul National University College of Medicine, Seoul University of Singapore, Kandang Kerbau Hospital, Singapore Prostaglandins
Rep. of Korea Singapore
Termination of Pregnancy: Australia
University of Sydney, Sydney, N.S.W.
Vaginal Rings and Intra-Cervical Devices Australia Japan University of Sydney, Sydney, N.S . W. University of Newcastle, Newcastle, N.S.W. Yamagata University School of Medicine, Yamagata Niigata University, Niigata St. Marianna University School of Medicine, Kawasaki City Reprodu c tive Biology Centre, Philippine General Hospital, Manila Seoul National University College of Medicine, Seoul University of Singapore, Kandang Kerbau Hospital, Singapore
Philippines Rep. of Korea Singapore
Indigenous Plants for Fertility Regulation Australia Hong Kong Rep. of Korea University of Sydney, Sydney, N.S.W. Chi n ese University of Hong Kong Seoul National University College of Medicine, Seoul
WPR/RC38/7 Add. 1 page 14
Methods for the Regulation of Male Fertility Australia Monash University, Prince Henry's Hospital, Melbourne, Victoria Commonwealth Serum Laboratories, Parkville, Victoria University of Sydney, Sydney, N.S.W. University of Hong Kong Chinese University of Hong Kong National Research Institute of Family Planning, Beijing Nanjing Institute of Materia Medica, Nanjing Shanghai Institute of Materia Medica, Shanghai Ministry of Public Health, Beijing Family Planning Research Institute of Sichuan, Chengdu Seoul National University College of Medicine, Seoul Korean Research Institute of Chemistry Technology, Chung Nam
Hong Kong People's Republic of China
Rep. of Korea
Birth Control Devices Australia University of Melbourne, Parkville, Victoria Flinders University of South Australia, Adelaide Australia National University, Canberra ICI Australia, Limited, Ascot Vale, Victoria Royal Melbourne Hospital, Parkville, Victoria University of Newcastle, Newcastle, N.S.W. University of Sydney, Sydney, N.S.W. University of Queensland, Brisbane, Queensland Yamagata University School of Medicine, Yamagata Kyoto University, Kyoto Hyogo Medical College, Hyogo-ken People's Republic of China Jinan University, Canton
Intranasal Administration of Steroids for Fertility Regulation Australia Rep. of Korea University of Sydney, Sydney, N.S.W. Seoul National University College of Medicine, Seoul
Psychosocial Research in Family Planning Australia Australia National University, Canberra University of the South Pacific Hong Kong University of Hong Kong Yamagata University School of Medicine, Yamagata
WPR/RC38/7 Add. 1 page 15
Malaysia Philippines
Institute for Medical Research, Kuala Lumpur University of the Philippines, Ermita, Manila Reproductive Biology Centre, Philippine General Hospital, Manila University of the Philippines. Quezon City Institute of Philippine Culture, Ateneo de Manila University, Manila Yonsei University, Seoul Chung Ang University, Seoul Seoul National University College of Medicine, Seoul Kore<;1n Institute for Family Planning, Seoul
Rep. of Korea
Prevention and Management of Infertility Australia Monash University, Clayton, Victoria University of Sydney, Sydney, N.S.W.
Vietnam Rep. of Korea Singapore
Institute of Gynecology and Obstetrics, Hanoi Seoul National University College of Medicine, Seoul University of Singapore, Kandang Kerbau Hospital, Singapore
Behavioural and Social Determinants of Fertility Regulation Malaysia People's Republic of China Philippines National Family Planning Board, Kuala Lumpur National Research Institute of Family Planning, Beijing
National Family Planning Office, Ministry of Health, Manila Population Center Foundation, Makati, Rizal Jose Fabella Memorial Hospital, Manila Notre Dame University, Cotabato City Leyte State College, Tacloban City Soon Chun Hyang College of Medicine, Onyang Seoul National University College of Medicine, Seoul Yeungnam University College of Arts and Sciences, Kyongsan, Kyongbuk Ynosei University, Seoul Korean Institute for Family Planning, Seoul University of Singapore, Singapore
Rep. of Korea
Singapore
WPR/RC38/7 Add. 1
page 16
Safety and Efficacy of Fertility Regulating Methods New Zealand People's Republic of China University of Otago. Dunedin Beijing Medical College, Beijing
Post-Ovulatory Methods of Fertility Regulation Vietnam Institute of Gynecology and Obstetrics, Hanoi Keio University School of Medicine, Tokyo Singapore University of Singapore, Kandang Kerbau Hospital, Singapore
Termination of Pregnancy (Current Methods) Malaysia Rep. of Korea Singapore University of Malaya, Kuala Lumpur Seoul National University College of Medicine, Seoul IPPF - Planned Parenthood Federation of Korea, Seoul University of Singapore, Kandang Kerbau Hospital, Singapore
Institutions receiving funds from Resources for Research PEOPLE'S REPUBLIC OF CHINA Department of Physiology Beijing Medical University Beijing Department of Family Planning Capital Institute of Medicine Beijing Division of Reproductive Endocrinology Peking Union Medical College Beijing National Research Institute for Family Planning (NRIFP) Beijing Department of Obstetrics and Gynaecology Peking Union Medical College Beijing Reproductive Medicine Research and Training Centre Beijing Medical University Beijing Primate Research Centre Fuzhou
WPR/RC38/7 Add.l page 17
Family Planning Research Institute of Guangdong Guangzhou Family Planning Research Division of 1st Aftd. Hospital Sun Yat Sen University Guangzhou Zhejiang Family Planning Research Institute Zhejiang Academy of Medicine Hangzhou Biochemistry Laboratory of Family Planning Zhejiang Medical University Hangzhou Medical Primate Research Centre of China Kunming Shanghai Institute of Materia Medica Academia Sinica Shanghai Shanghai Institute of Planned Parenthood Research Shanghai Shanghai Institute of Biological Products Shanghai Research Institute of Obstetrics and Gynaecology Shanghai Medical University Shanghai Shanghai Institute of Cell Biology Academia Sinica Shanghai Division of Reproductive Biology Research Hebel Medical College Shijiazhuang Second Teaching Hospital Tianjin Medical College Tianjin Tianjin Municipal Research Institute for Family Planning Tianjin Family Planning Research Institute Tong Ji Medical University Wuhan
WPR/RC38/7 Add.l page 18
PHILIPPINES
UP PGH Reproductive Health Care Centre Manila
Jose Fabella Memorial Hospital Comprehensive Family Planning Centre Manila
SINGAPORE VIETNAM
University Department of Obstetrics and Gynaecology Singapore Institute of Gynaecology and Obstetrics Hanoi
Research Training Grants Awarded in the Western Pacific Region Australia People's Republic of China Vietnam Hong Kong Japan Malaysia Philippines Rep. of Korea Singapore Total number of grants for WPR
6 275 15 7 11 6 23 17 __ll 373
====
SCIENTISTS FROM WPRO
COUNTRY
NAME
SEX
COMMITTEE
START
END
AUSTRALIA
BASTEN, Dr A. BURGER, Dr H. FINDLAY, Dr J. FRASER, Dr I.S. KERR, Dr J. SHORT, Dr R. Dr Dr Dr Dr Dr Dr Dr Dr Dr Dr CHEN Jung-kang GE Qin-sheng Lin Chung-min QIAN Shao-zhen QIU Shu-hua SANG Guo-wei WANG Yi-fei wu Chieh-p'ing XIAO Bi-lian ZHENG Huaimei
M M H
M M M M F H
Vaccines Natural Regulation Review Group Long-acting Agents Toxicology Group STAG Post-ovulatory Infertility Plants l1o.le Safety and Efficacy Long-acting Agents Vaccines STAG Standardization and Quality Review Group Post-ovulatory Male STAG CRR CRR Safety and Efficacy
1985 1983 1985 1983 1984 1983 1987 1985 1981 1983 1985 1983 1986 1985 1984 1986 1985 1984 1985 1987 1985 1985 1985 1985 1987 1986 1985
1987 1988 1987 1987 1989 1988 1989 1987 1986 1988 1987 1988 1988 1988 1986 1988 1987 1989 1988 1989 1987 1987 1987 1987 1989 1989 1987
CHIN"A
M F M M M F F F F
HONG KONG
MA, Dr J.L. WANG, Dr c. MURAHATSU, Dr M. WAGATSUMA, Dr T. KHOO, SKEGG, Dr S.E. Dr D. Dr M.
JAPAN MALAYSIA NEW ZEALAND PHILIPPINES SAHOA SINGAPORE
M M F
M F
~~ OQ:;:d
ro1-'C":I
CONCEPCION, ANANDALE, Dr
BSD Long-acting Agents Post-ovulatory STAG Infertility
\0 (,)
v.
F F
00
:::0
.......
CHEANG, Dr A. RATNAM, Dr s. WONG, Dr P.C.
6: ~
M M
1-'
WPRO PAST GONMITTEE NEMllERS
AUSTRALIA
BRIGGS, Ur 11. H. Dr H. CALDWELL, Ur J. DE KRETS£K, Dr D. ~UKGER,
M M i:1
H M M H N
FRASER, Ur I. S. HUDSON, Ur ~. JONES, Dr w. HlTCHt:LL, Or (;. Rt:INK.EN, Dr J. :>H.t::ARNAN, L.lr R.
F M M 1'1
SHORT, Dr K. V. SLAYTOR, Vr H. WHITE, Dr I.G. CHlNA, PEOPLE'::> .t<.£PUBLIC OF Or Or Dr Dr Dr
H H
Toxicology Review Panel Oral contraceptives Natural methods Advisory Group Advisory Group Infertility Long-acting agents Male methods Vaccines Vaccines Service research Advisory Group Long-acting agents Review Group Male methods Plants Vaginal rings (sperm migration) Standardization and quality Advisory Group Prostaglandins Prostaglandins IUDs Post-ovulatory Vaginal rings (svena migration) Hale methods Vaccines Oral contraceptives Male methods Post-coital and once-a-month drugs Advisory Group Long-acting agents Hale methods Post-coital and once-a-month drugs Oral contraceptives lUDs
1976 1977
1982 l9ts2 B83
1974 1971 1980 1978 1976 H74 1978 1974 197~
1973 1982 .L9d4
1:179 .i.978 B84 B7 ~ 1979 J.')]':J
1977 1973 1972 1976 1976 1972 1981 1975 1980 1980 1984 1984 1980
.i975 1978 l97':J
1979 1')77
Dr Ur
Dr Or Dr Dr Dr
BING Sneng-min CH'EN Wen-chen CHEN Jia-zheng CHOU Yu-fen GAO Ji H:JlEil cnung-ming J H~ Zuao-y i ug Ll::l Hai-peng LlU Xue-6ao ~dl Yonc:-en ::>UN Yi -bin IW Xi-L-ui
1984 1977
F F H F H F H H N
1980 1983 B84 1986 1980
1982
1982 1':184 1::184 1982 .i98U .i%1 .1~!;2
19H 19!;4 l1Jcl2
!Jr X lAO .iH l.i an J..Jr XU.E Sl1<~-1JU
H t-1 F
1979 197') l9d0 1~79
..
,
Dr YAN(; Y.i.-cllien Dr ZHAH(; Dewei Dr ZHAI"J(.; pei -:t.IIU
H H
1~79
1')79 1':J<3J
B78
198J 1')84
F
1'Joo
riONG KONG
KONG, Or Y.C.
MA, Dr H.-K.
0, Dr w.s. WOHG, Dr P.Y.U. HIROl, Dr H. HOlUO, Dr H. SAKANOTU, J.).r ::i. WAGAT::iUHA, Dr T.
M F F
H H
Plants Prostaglandins Post-coital and once-a-month drugs Male methods Review Group Vaginal rin~s (sperm migration) Natural methods Prosta~landins
1978 1979 1979 1982 1978 1975 19131 1977 1977 1977 1979 1977 1979 1974 1983 1980 1977 1978 1980 1984 1971 1974 1';77 19~2
1979 1983 1981 1982 1984 1979 1983 l91B 1983
JAPAN
rt rl 11 H
IUDs Psychosocial Service research Post-coital and once-o-Donth drugs Psychosocial Sequelae of abortion Male lUOs Service research Review Group Va~inal rings (sperm migration) Toxicolog~ Group Long-acting agents Sequelae of abortion IUOs Advisory Group Oral controceptiv~s Female sterilizatiun Review Group Service research Py s Cl1osoci al Review Group Sequelae of abortion Standardization and quality
KOK.t::A, l<EPUoL.IC OF
AriN, Or t<..C. .dANG, Dr s . CHU, Ur W .K. CHUNG, Dr J.(.K. HONG, Dr S.H. LJ::E, Dr rl.Y. 'fCrlAI, Vr H. WOONG HONG, Dr J. KIM, Dr s. YANG, Dr K. H.
.rl i'l H M
.H ri
1979 1981 1978 1981 1981 1985 1~83
H H M
1978 19rl4 1980 1986 19tH 1981
HALAY::ilA i~.I::W
Arl.SHAT, Dr H. ::ilNNATHUKAY, Dr 'f.A. ~J lLSON,
a H H 11
L..I::ALANO
ur £.
1Ylo l~84 "0~
.PHlLlPPINE.:i
APELO, Dr tC RAHUS, Or K.
1977
19du H79 B84 l9tll.
OQ:;d
Ill '"d
1973 1~nn
co:;d
F
....... w
NC")
H77 l~7Y
S1NGAPUK£
AKCJ::, Or W.
CHENG, Dr H. GOH, Dr V.
N l1 (•1
Hlb !'j]l.
1980 191:)4
00 -...J
6: 0.
1980
l'i77 l YtU
.......
SINGAPUllli
GWEE, Dr l'l.C.£. KAlUH, Or NG, Dr C. H.ATNAL'i, ~.
(continued)
PRASAU, Ur H..
Toxicology Group .Prostaglandins Oral contraceptives Post-ovulatory CHi
1980 1976 1978 1982 1979
l9t36 19tH
19tH 1987 1984
Dr S.S. F
RAUFF, Dr M.
Va6inal rings (sperm migration) Sequelae of abortion Female sterilization
1976 1976 1981
197!1 1981 1984
WORLD HEALTH ORGANIZATION
ORGANtSATION MONDIALE DE LA SANTE
REGIONAL OFFICE FOR THE WESTERN PACIFIC BUREAU R~GIONAL DU PACIFIQUE OCCIDENTAL
REGIONAL COMMITTEE Thirty-eighth session Beijing 8-14 September 1987 Provisional agenda item 12
WPR/RC38/7 18 May 1987 ORIGINAL: ENGLISH
SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION: MEMBERSHIP OF TilE POLICY AND COORDINATION ADVISORY CQMMITI'EE Report by the Regional Director
The Policy and Coordination Advisory Committee (PCAC) act§ ~~ ~n advisory body to the Director-General on matters related to the Special Programme of Research, Development and Research Training in Human Reproduction. PCAC is composed of four categories of member from the varioua Member States. Category (b) membership is composed of twelve members elected by the WHO regional committees. Three members have been allocated to the Western Pacific Region under this category. The term of one category (b) member will expire on 31 December 1987. The Regional Committee is requested to elect one member to represent the Region under category (b), effective 1 January 1988.
WPR/RC38/7 page 2
The terms of reference of the Policy and Coordination Advisory Committee (PCAC), including membership, were approved by the Advisory Committee in 1984 and reaffirmed at the 1985 meeting (see Annex 1). There are four categories of member: (1) Category (a) is composed of the twelve largest financial contributors to the Special Programme in the previous year. Category (b) is composed of twelve members elected by the WHO regional committees with one-third of the twelve rotating off the Committee each year. In selecting members, the regional committees will be asked to take into account a country's financial and/or technical support to the Special Programme as well as its interest in human reproduction as demonstrated by national policies. The Western Pacific Region has been allocated three members. Category (c) is composed of up to three members to be elected by PCAC for one-year terms. Candidates from governments, agencies, foundations and other bodies may declare their interest sixty days in advance of the PCAC meeting. Member States have already been approached informally through the WHO Representatives for nominees to · this category to be elected at the next meeting of PCAC on 20-22 May 1987. (4) Category (d) is composed of one representative each of the International Planned Parenthood Federation, the United Nations Fund for Population Activities and the World Bank.
(2)
(3)
According to the rotating system adopted for the terms of office of PCAC members, the present status of category (b) members elected by the Regional Committee at its thirty-seventh session from among Hember States of the Western Pacific Region is as follows: Member Viet Nam Republic of Korea Singapore Viet Nam Year elected 1986 1986 1986 1986 Term of office September 1986 - 31 December 1986 September 1986 - 31 December 1987 September 1986 - 31 December 1988 1 January 1987 - 31 December 1989
It will be noted that the term of the Republic of Korea under category (b) membership will expire on 31 December 1987. In order to fill this vacancy, it will be necessary for the Regional Committee to elect at its thirty-eighth sessi on one member from the Western Pacific Region under category (b) for t he period 1 January 1988 to 31 December 1990.
WPR/RC38/7 page 3/4
The members of PCAC under category (b) will all be elected for a term of three years once the rotating system is established; onethird of the members will rotate off each year. It should be noted that the major donor countries comprising category (a) are not eligible for election under category (b). The countries concerned in this Region are Australia, China and the United Kingdom.
WPR/RC38/7 page 5 ANNEX 1 POLICY AND COORDINATION ADVISORY COMMITTEE Terms of reference 1 Functions The PCAC shall act as an advisory body to the Director-General of WHO, making recommendations on matters related to the policies, strategies, financing, overall organization, management and impact of the WHO Special Programme of Research, Development and Research Training in Human Reproduction (HRP). Membership Membership of the Committee shall not exceed 30. Due consideration shall be given to a regional distribution, keeping in mind the relative importance ascribed to research in fertility regulation in different parts of the world. Its membership shall be as follows: (a) Largest financial contributors The 12 countries which were largest financial contributors to the Programme in the previous year. (b) Countries elected by WHO regional committees regional Twelve member countries elected by the WHO committees for three-year terms with one-third rotating off each year. When electing members, the regional committees will be asked to take into account a country's financial and/or technical support to the Programme as well as its interest in the field of population/family planning as demonstrated by national policies and programmes. (c) Other interested countries and nongovernmental agencies Up to three members to be elected by PCAC for one-year terms. Governments, agencies, foundations and other bodies may declare their candidacy 60 days in advance of the PCAC meeting when selection will be made, which will be the meeting prior to the one to be attended. (d) Permanent members The following three organizations - United Nations Fund for Population Activities, World Bank and International Planned Parenthood Federation which, by their policies and financial/operational contributions, have shown an interest in the field of population/family planning.
1Amended by PCAC at its 25-27 November 1985 meeting.
WPR/RC38/7 Annex 1 page 6
Observers from other Member States of WHO and other agencies/programmes may attend at the discretion of the Director of the Programme in consultation with Chairman, PCAC. Observers will be expected to cover their own expenses. Operation The PCAC Secretariat. Chairman shall meet annually; WHO shall provide the
A Chairman shall be elected by PCAC at the beginning of each meeting from members of categories (a) or (b) and will serve for a twoyear term. In addition to Chairman shall: presiding over the meeting, the
- attend meetings of the Scientific and Technical Advisory Group (STAG) - undertake such additional assigned by the PCAC. Rapporteur Stag Travel expenses duties as may be
A Rapporteur shall be selected by PCAC at the beginning of each meeting from among its members. The Chairman of STAG the meetings of PCAC. shall attend and report to
All members shall make their own arrangements to cover the expenses incurred in attending sessions of the PCAC. The WHO Director-General may make special arrangements for developing countries upon request.
Procedures The PCAC procedure. shall normally be guided by the WHO rules of
In consultation with the Chairman, the Secretariat shall prepare an annotated provisional agenda for the meeting. Points for decision should be adopted and duly the conclusion of the meeting. recorded before
A report, prepared by the Rapporteur, with the assistance of the Secretariat, shall be circulated as soon as possible after the conclusion of the meeting for subsequent approval by participants.